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Orthotopic heart transplantation improves life expectancy and quality of life in patients
with severe heart failure. After transplantation, metabolic complications are frequent.
They are caused particularly by immunosuppressive therapy. In our cohort of 315 patients,
52% of patients had diabetes mellitus together with hyperlipoproteinemia, 41% of patients
had hyperlipoproteinemia without diabetes, 3% of patients had diabetes mellitus without
hyperlipoproteinemia and only 4% of patients had none of these disorders. Therapeutic
options with respect to interactions with immunosuppressive therapy are discussed in this
article.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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In the last two decades, orthotopic heart transplantation
(HTX) has become an established method for the treatment
of severe heart failure. Heart transplantation is a treatment
option that signiﬁcantly improves quality of life and prog-
nosis of patients with terminal heart failure. Owing to long-
term survival of transplanted patients, this treatment is
associated with various late complications. The most impor-
tant complications are rejection, infection, or cancer, but also
metabolic complications, accentuated by lifelong immuno-
suppressive treatment.
1.1. Metabolic syndrome
Metabolic syndrome is a cluster of typical risk factors, which
often occur together and arise from insulin resistance. It is
ranked among diseases of afﬂuence. Presence of metabolic
syndrome increases the chance of developing premature ather-
osclerosis and cardiovascular diseases and also increases the
risk of developing type 2 diabetes mellitus and some frequent
types of cancer. Metabolic syndrome according to the Czech
Institute of Metabolic Syndrome is deﬁned as the presence of at
least 3 risk factors listed below:(1) Central obesity—waist circumference ≥102 cm in men,
≥88 cm in women(2) Triglycerides ≥1.7 mmol/L (or hypolipidemic therapy)
(3) HDL cholesterol o1.0 mmol/L in men, o1.3 mmol/L in
women
(4) Blood pressure ≥130/≥85mmHg or antihypertensive therapy
(5) Fasting plasma glucose ≥5.6 mmol/L, or impaired glucose
tolerance, or type 2 diabetes mellitus
1.2. Hyperlipoproteinemia
Hyperlipoproteinemia occurs in 60–80% of patient after heart
transplantation. It is associated with several risk factors as
history of coronary artery disease, history of lipid abnormal-
ities, body mass index ≥25 kg/m2, high dose of corticoster-
oids, and cyclosporine or sirolimus administration.
Cyclosporine increases cholesterol level, particularly its
LDL fraction [1]. One of the possible mechanisms is injury of
cell membrane, which is involved in LDL cholesterol clear-
ance. This can probably lead to LDL cholesterol rise [2]. Higher
plasmatic concentrations of cyclosporine decrease activity of
lipoprotein lipase, which can cause increase in triglyceride
level. Changes in lipid metabolism occur already in the ﬁrst
3–6 months after transplantation [3]. Cyclosporine decreases
clearance of prednisone, which can cause insulin resistance,
increased synthesis of free fatty acids, and increased produc-
tion of VLDL particles [4].
Newer immunosuppressive agent, calcineurin inhibitor
tacrolimus has a less adverse effect on lipid proﬁles than
cyclosporine. In the retrospective study of 194 patients after
heart transplantation who were switched from cyclo-
sporine to tacrolimus, levels of total and LDL cholesterolsigniﬁcantly decreased, and levels of HDL cholesterol signiﬁ-
cantly increased [5].
A negative effect of sirolimus (rapamycin) on lipid proﬁles
has also been reported. The data were mostly gathered from
patients after kidney transplantation. In a group of patients
after kidney transplantation where sirolimus had been added
to cyclosporine with corticosteroids, cholesterol and trigly-
ceride levels increased signiﬁcantly. The rise was dependent
on the dose of sirolimus [6].
There is not enough data evaluating the effect of myco-
phenolate mofetil on lipid levels after organ transplantation.
Corticosteroid administration is associated with increased
hepatic production of VLDL and rise in triglycerides and total
cholesterol levels. It is caused by increased activity of acetyl-
CoA carboxylase, increased synthesis of free fatty acids, and
inhibition of lipoprotein lipase. Moreover, these effects are
emphasized by cyclosporine, which decreases prednisone
clearance.
1.3. Diabetes mellitus
According to ISHLT registry, the prevalence of diabetes
mellitus before heart transplantation was 22%, and cumula-
tive incidence of new-onset diabetes was up to 32% in the
ﬁfth year after heart transplantation [7]. Risk factors for
developing diabetes mellitus that were reported in patients
after liver or kidney transplantation were diabetes in family
history, age over 40 years, metabolic syndrome, impaired
glucose tolerance before transplantation, hepatitis C, immu-
nosuppressive drugs, or obesity. In one study, family history
and higher glycemia before transplantation (5.6 vs. 5.2 mmol/L
in patients who did not develop diabetes) were found to be
predisposing factors for developing diabetes mellitus after
heart transplantation [8].
The major predisposing condition in the development
of diabetes mellitus is the treatment with corticosteroids,
though other immunosuppressants, particularly tacrolimus,
contribute to its development as well [9].2. Results
A total of 315 patients after heart transplantation treated at
our department were included in this study. This represen-
tative sample comprises 263 men and 52 women. The aim of
our study was to explore how many patients after heart
transplantation suffer from diabetes mellitus and/or hyperli-
pidemia, and also how are these disorders treated in this
setting.
After data collection, all patients were divided in four
groups as shown in Fig. 1 (numbers of patients are listed
below): Patients with diabetes mellitus and hyperlipidemia—165.
 Patients with diabetes mellitus and without hyperlipidemia
—9. Patients without diabetes mellitus and with hyperlipidemia
—128. Patients without diabetes mellitus and without hyperlipi-
demia—13.
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Fig. 2 – Total numbers of patients with hyperlipoproteinemia
and diabetes mellitus.
Table 1 – Treatment of hyperlipidemia.
Treatment n
Fluvastatin 173
Simvastatin 47
Atorvastatin 50
Fenoﬁbrate 3
Ezetimibe+Fluvastatin 4
Diet low in fat 16
Table 2 – Treatment of diabetes mellitus.
Treatment n
Diabetic diet 48
Insulin 60
Gliclazide 17
Glimepiride 19
Gliquidone 11
Glipizide 3
Metformin 12
Sitagliptin 2
Glibenclamide 2
HLP+,DM+
HLP+,DM-
HLP-,DM+
HLP-,DM-
52% 41% 
4% 3% 
Fig. 1 – Patients divided in 4 groups according to the
presence of hyperlipoproteinemia and diabetes mellitus.
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293 patients had hyperlipidemia, and 13 patients had none of
these disorders (Fig. 2). As regards to hyperlipidemia, patients
were treated with low-fat diet and ﬁve various lipid lowering
agents (Table 1). Apart from diet, patients with diabetes were
treated with eight various antidiabetic agents, including
insulin. Numbers of patients are listed in Table 2.3. Discussion
3.1. Hyperlipidemia
Hyperlipidemia was found in 93% of patients after HTX in our
study. Such high prevalence rates up to 80% in patients after
HTX have been reported also in studies of other authors.
Hyperlipidemia occurs after HTX more often than after
transplantation of other organs, which is probably due to
higher prevalence of hyperlipidemia before transplanta-
tion and also a consequence of more intensive immuno-
suppressive regimen after HTX than after kidney or liver
transplantation. The major cause of hyperlipidemia after HTX
is immunosuppressive therapy. In the study covering years
1968–1989, Taylor et al. have reported that major predispos-
ing conditions for lipid abnormalities after transplantationare prednisone administration and coronary artery disease
before transplantation [10]. The other important factor is
weight gain after surgery caused by improved absorption
and utilization of nutrients due to better perfusion of gastro-
intestinal tract. Elevation of total cholesterol and LDL choles-
terol in the ﬁrst year after HTX is associated with worse
prognosis. Therefore, statin administration is indicated
already in early postoperative period [11].
Cyclosporine and tacrolimus both inhibit the metabolism
of those statins metabolized by cytochrome CYP 450 3A4 (i.e.,
atorvastatin, lovastatin, simvastatin or rosuvastatin), and
this drug interaction leads to elevated plasmatic concentra-
tions of these statins and higher risk of statin-induced
myopathy. By contrast, pravastatin is not metabolized via
cytochrome CYP 450 and ﬂuvastatin is metabolized via CYP
450 2C9. Both are suitable for the treatment of transplant
patients because the risk of drug interactions through CYP
450 3A4 is minimal [11–13].
In our cohort of patients after HTX, the most frequent
hypolipidemic agent was ﬂuvastatin, which was used in 60%
of patients.
Statin administration can be started early after HTX with
low doses of any statin (atorvastatin 10 mg, lovastatin 20 mg,
simvastatin 10 mg, rosuvastatin 5 mg, pravastatin 20–40 mg,
ﬂuvastatin 40 mg) [12]. Adverse effects of statins have to be
considered before the treatment is launched, particularly
myalgia (muscle pain without creatine kinase elevation),
myositis (muscle weakness and pain with creatine kinase
elevation), and rhabdomyolysis (muscle symptoms, creatine
kinase elevation up to 10 times the upper limit of normal,
serum creatinine elevation, urine myoglobin elevation).
These adverse effects occur rarely with statin monotherapy,
but are more often observed in patients using cyclosporine
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effective, high doses of statins or combination with ﬁbrates
are not recommended since the use of these regimens is not
supported by the results from prospective trials [13].
If statins are not effective enough cyclosporine can be
switched to tacrolimus because immunosuppressive regi-
mens with tacrolimus have better lipid proﬁles in comparison
to cyclosporine [14]. The fact has been conﬁrmed in study by
White, in which one half of 129 patients were switched to
tacrolimus, and the other continued with cyclosporine. In
patients who switched to tacrolimus, total cholesterol, LDL
cholesterol, apolipoprotein B, and also blood urea nitrogen,
creatinine, and uric acid decreased signiﬁcantly. It should be
noted that blood glucose, hemoglobin A1c, and insulin levels
did not deteriorate. Statins were used in 80% of patients, most
frequently pravastatin in mean dose of 25 mg or atorvastatin
in mean dose of 25 mg [15].
We should also attempt to decrease or completely dis-
continue treatment with corticosteroids in this case [16].
Recently, some data has been published supporting admin-
istration of atorvastatin in patients after transplantation, which
is more effective than treatment with pravastatin or ﬂuvastatin.
In the study of Patel, patients with persisting LDL cholesterol
elevation on pravastatin, ﬂuvastatin, or simvastatin therapy
were switched to atorvastatin. The initial dose of atorvastatin
was 10mg, and the most frequent dose was 20mg. Patients
were closely monitored. Treatment with atorvastatin was
effective and caused further decrease of LDL cholesterol with
minimal adverse reactions [17].
When atorvastatin is started, conversion to tacrolimus is
safer and more efﬁcient [18].
Pilot studies evaluating safety and efﬁcacy of rosuvastatin
therapy in patients after heart transplantation have been
published recently. One of the ﬁrst studies illustrates safety
of rosuvastatin in doses 5 mg and 10 mg in 21 patients after
heart transplantation, who had unsatisfactory lipid levels
with higher doses of statin in monotherapy. Nine patients
used atorvastatin, nine patients had pravastatin, two patients
had simvastatin, and one patient used ﬂuvastatin in
this group. After substitution of these statins with rosuvas-
tatin in dose 5 mg or 10 mg, total cholesterol, LDL cholesterol
and triglycerides decreased signiﬁcantly within 6 weeks of
treatment. No liver enzymes or creatine kinase alterations or
myositis has been reported during safety monitoring [19].
There is still not enough data on efﬁcacy and safety of
combination therapy with statin and ezetimibe. Therefore, a
multicenter, double-blind, comparative study with sufﬁcient
number of patients comparing individual statins and also
combination of statin with ezetimibe would be very helpful.
3.2. Diabetes mellitus
Diabetes mellitus is frequent after transplantation and con-
tributes to development of allograft vasculopathy. More
robust data on comparison of cyclosporine and tacrolimus
with regard to new-onset diabetes mellitus has been pub-
lished in patients after kidney and liver transplantation.
Results of these studies show higher incidence of diabetes
in patients using tacrolimus. For patients after heart trans-
plantation, we have less data, but they also conﬁrm previousﬁndings. In one study, insulin-treated diabetes was present in
7.0% of patients on tacrolimus and only in 4.3% patients on
cyclosporine therapy after heart transplantation in the ﬁrst
year [20]. In the study of Nikolaidis et al., diabetes mellitus
was reported in 38% of patients after heart transplantation
(82 out of 215 patients). Majority of diabetic patients were
treated with insulin (67%); 54% of patients were treated with
insulin in monotherapy, and 13% of patients had insulin
combined with oral antidiabetics (OADs). 18% of patients
were treated solely with OADs, and 15% of patients were
treated with diabetic diet only. Mean level of hemoglobin 1Ac
was 7.7 g/dL. Only one third of patients had hemoglobin A1c
lower than 7 g/dL. The highest concentrations of hemoglobin
A1c had patients treated with prednisone than patients on
sirolimus or tacrolimus. The best results were found in patients
treated with cyclosporine [21].
In our cohort, diabetes mellitus was found in 174 patients
(55%) after heart transplantation, of whom 165 (52%) had also
hyperlipoproteinemia, and 9 (3%) had normal lipid levels.
Diabetes mellitus was treated with insulin in 60 patients
(34%), with OADs in 66 patients (38%), and only with diet in 48
patients (28%). Most frequently used oral antidiabetic was
glimepiride in 19 patients (11%) followed by gliclazide in 17
patients (10%). The other drugs are listed in Table 2.
Diabetes should be treated according to the guidelines of
the Diabetes Society since the data on the treatment of
small group of patients after organ transplantation or more
precisely heart transplantation are limited. Prevention,
early diagnosis, and proper treatment of diabetes are crucial.
Patients should be followed closely: blood glucose levels,
results of oral glucose tolerance test, and eventually hemo-
globin A1c concentrations have to be checked regularly.
Immunosuppressive regimens with lower doses of calci-
neurin inhibitors are preferable. Associated risk factors as
hyperlipidemia and hypertension have to be carefully treated
[22]. If therapeutic goal is not achieved with lifestyle mod-
iﬁcation, then therapy with OADs should be started. Studies
comparing these drugs in patients after organ transplanta-
tion have not been performed yet. The suitable agent should
be chosen according to its tolerability and safety proﬁle. If
OADs administration is not safe, or lowering of fasting
plasma glucose levels under 6.7 mmol/L, or random blood
glucose levels under 8.9 mmol/L, or hemoglobin A1c under
6.5% is not achieved, insulin should be started. Insulin should
be also used at the time of metabolic decompensation [23].
3.3. Metabolic syndrome
The occurrence of metabolic syndrome has been evaluated in
the epidemiologic study named TRACA (TRAnsplant CArdi-
aco) in patients after heart transplantation. Prevalence of
metabolic syndrome was 42%. Metabolic syndrome was more
frequent in patients with coronary artery disease before
transplantation than with other diagnoses (52% vs. 27%) [24]
Hyperlipoproteinemia and diabetes mellitus were found
simultaneously in 165 patients (52%) in our cohort.
Metabolic syndrome before transplantation is another risk
factor of long-term survival. Data of 797 patients treated in
years 1992–2008 were reviewed in a retrospective study.
Metabolic syndrome, deﬁned as the presence of at least three
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with BMI more than 30 kg/m2), was found in 28% of patients
before transplantation. Patients with metabolic syndrome
prior to surgery were older and had more often hypertension,
diabetes mellitus, renal involvement, and coronary artery
disease. Early post-transplant complications were equally
frequent in patients with and without metabolic syndrome.
However, survival was signiﬁcantly different in both groups.
In patients without metabolic syndrome, ﬁve-, ten- and
ﬁfteen-year survival rates were 92%, 80%, and 55% while in
patients with metabolic syndrome, they were 88%, 72%, and
38%. Metabolic syndrome prior to transplantation remains an
important risk factor even after normalization of hemody-
namic status after transplantation. The longer the survival
after transplantation, the more pronounced the difference
between groups is [25].
Patients with metabolic syndrome diagnosed before or
after transplantation have more often allograft vasculopathy.
The more criteria according to ATP III are present, the more
frequent vasculopathy is [26].4. Conclusions
Heart transplantation is a successful method for the treat-
ment of severe heart failure, which resolves patient's hemody-
namic impairment. However, after transplantation, metabolic
problems are accentuated. They contribute particularly to
acceleration of allograft vasculopathy, and they also have
considerable impact on long-term prognosis. Hyperlipoprotei-
nemia and diabetes mellitus are the most important metabolic
risk factors of coronary events after organ transplantation in
general, including heart transplantation. It is important to try to
positively inﬂuence those factors both with lifestyle modiﬁca-
tion and pharmacotherapy.Acknowledgments
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